Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chrome Holding Co's Days Sales Outstanding for the
three
months ended in Jun. 2025 was 4.63.
Chrome Holding Co's Days Inventory for the
three
months ended in Jun. 2025 was 111.19.
Chrome Holding Co's Days Payable for the
three
months ended in Jun. 2025 was 75.2.
Therefore, Chrome Holding Co's Cash Conversion Cycle (CCC) for the
three
months ended in Jun. 2025 was 40.62.
Chrome Holding Co (OTCPK:MEHCQ) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Chrome Holding Co Cash Conversion Cycle Related Terms
Chrome Holding Co Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Chrome Holding Co's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEHCQ vs BDSX, XGN, FONR: Cash Conversion Cycle Comparison
For the Diagnostics & Research subindustry, Chrome Holding Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chrome Holding Co Cash Conversion Cycle vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Chrome Holding Co's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Chrome Holding Co's Cash Conversion Cycle falls into.
Chrome Holding Co Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Chrome Holding Co's Cash Conversion Cycle for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chrome Holding Co (MEHCQ) has a Cash Conversion Cycle of 40.62 as of Jun. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Chrome Holding Co and its competitors.
Is Chrome Holding Co's Cash Conversion Cycle too high?
Chrome Holding Co's current Cash Conversion Cycle is 40.62. The Medical Diagnostics & Research industry median Cash Conversion Cycle is 72.23. Chrome Holding Co's value of 40.62 is 43.8% below this industry median. Overall, Chrome Holding Co has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Chrome Holding Co's Cash Conversion Cycle compare to BDSX and XGN?
Chrome Holding Co's Cash Conversion Cycle of 40.62 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Cash Conversion Cycle is 72.23. Chrome Holding Co's value of 40.62 is 43.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Diagnostics & Research company?
The median Cash Conversion Cycle among Medical Diagnostics & Research companies is 72.23, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chrome Holding Co's current Cash Conversion Cycle of 40.62 is 43.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Chrome Holding Co and its competitors. For the Medical Diagnostics & Research industry, the median Cash Conversion Cycle is 72.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chrome Holding Co's current Cash Conversion Cycle is 40.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chrome Holding Co stock overvalued right now?
Chrome Holding Co (MEHCQ) has a current Cash Conversion Cycle of 40.62. The current Cash Conversion Cycle is 40.62 and 43.8% below the Medical Diagnostics & Research industry median of 72.23. Chrome Holding Co's overall GF Score™ is 58/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Chrome Holding Co (MEHCQ), the current Cash Conversion Cycle is 40.62 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Chrome Holding Co, formerly known as 23andMe Holding Co, is a consumer-facing healthcare technology company, involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes one main sector that is Consumer and Research Services. The company generates maximum revenue from the Consumer and Research Services segment.
58GF Score
Get the complete analysis for MEHCQ
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEHCQ has been successfully added to your 
